Freezing of Gait in Parkinson’s Disease: Risk Factors and Associated Nonmotor Symptoms
Objective: To clarify risk factors for, and clinical associations of, freezing of gait (FOG) in Parkinson's disease (PD). Background: FOG is a disabling and incompletely…Moaning: genetic analysis of a family with eight affected members
Objective: To report the clinical and genetic evaluation of a five-generation family with eight members exhibiting moaning. Background: Moaning is characterized by low-tone abnormal involuntary,…Gene Expression Profiling of depression in Huntington’s disease
Objective: This preliminary study was designed to investigate the gene expression profile by RNA-seq in HD patients with depression and without depression, and between subjects…Neuroprotective and neurotrophic efficacy of Ginkgo biloba extracts against 3-nitropropionic acid-induced oxidative stress in a rat model of Huntington’s disease
Objective: The present study examined the potential neuroprotective and neurotrophic efficacy of GBE against 3-nitropropionic acid (3-NP)-induced oxidative stress in a rat model of HD…Huntington’s Disease Protein Huntingtin Associates with its own mRNA
Objective: To investigate how Htt might affect RNA metabolism we set out to purify and analyze RNA associated with Htt. Background: The Huntington's disease (HD)…Assessment of Caregiver Burden in Huntington’s disease
Objective: We aim to identify and characterize caregiver burden among HD caregivers, to see what aspects of HD caregiving are associated with the greatest burden…Enabling efficient use of digital health technologies to support Parkinson’s disease drug development through precompetitive collaboration
Objective: To describe the Critical Path for Parkinson’s (CPP) consortium approach to advance the field of digital technologies in clinical drug development for Parkinson’s disease…Dopamine receptor variants alter outcomes with levodopa in early-stage Parkinson’s disease
Objective: To examine if specific single nucleotide polymorphisms (SNPs) in the genes for dopamine receptors 2 and 3 (DRD2, DRD3) correlate with worse outcomes within specific…Analysis of the Shape of the Gocovri Steady-state PK Profile: Implications for an Extended Release Product
Objective: To demonstrate the unique shape and pharmacokinetic (PK) profile of Gocovri® (amantadine) extended release (ER) capsules by using metrics pertinent to ER dosage forms.…Changes in Supine Blood Pressure with Long Term Use of Droxidopa
Objective: To determine the long-term effects of droxidopa use on supine blood pressure (BP) in patients with neurogenic orthostatic hypotension (nOH). Background: nOH is a…
- « Previous Page
- 1
- …
- 120
- 121
- 122
- 123
- 124
- …
- 217
- Next Page »